# US 2012/0251576 A1 · Treatment of Nasal and Sinus Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251576 A1
- Document ID: US20120251576A1
- Status: Published application
- Kind: A1
- Application number: 13/516,338
- Filed: 2010-12-15
- Published: 2012-10-04
- Earliest claimed: 2009-12-15
- Inventors: Ira Sanders
- Web page: https://patentgrep.com/patent/US20120251576A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0043: {Nose}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 25/06: Antimigraine agents
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 31/04: Antibacterial agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating nasal and sinus conditions, and symptoms thereof, with botulinum toxin (BoNT).

## Claims

### Claim 1

A method of treating a nasal or sinus condition, or a symptom thereof, comprising administering a therapeutically effective amount of botulinum toxin (BoNT) to a selected site outside the nasal cavity of a mammal suffering from a nasal or sinus condition, or a symptom thereof, wherein the nasal or sinus condition, or symptom thereof, is treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the BoNT is administered by needle injection, microneedle injection, jet or pressure injection, or topical application.

### Claim 3 (depends on 1)

The method of claim 1, wherein the selected site is selected from the group consisting of: the nasal skin overlying the nasal cartilates, nasal bones, maxillary bones, lacrimal bones, ethmoid bone, or frontal bones; the nasal tip; the external nares; the nasal alae; the palpated bony margin of the pyriform aperture; the lacrimal sac or duct; the eyelid; under the lip; the gingival mucosa; the sphenopalatine foramen; and the infraorbital foramen.

### Claim 4 (depends on 1)

The method of claim 1, wherein the BoNT is delivered by needle injection through nasal, ethmoid, frontal, maxillary, or palatine bones.

### Claim 5 (depends on 1)

The method of claim 1, wherein the BoNT is delivered by jet or pressure injection across the anterior walls of the maxillary sinus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the nasal or sinus condition is selected from the group consisting of rhinitis, infectious rhinitis, allergic rhinitis, sinusitis, asthma, COPD, migraine headache, impaired cerebral blood flow, sleep breathing disorders, and ocular disorders.

### Claim 7 (depends on 1)

The method of claim 1, wherein the symptom is selected from the group consisting of nasal congestion, sneezing, rhinorrhea, postnasal drip, nasal or sinus pain, headache, coughing, wheezing, itching, redness, thickened nasal mucosa, and nasal polyp.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dose of BoNT is from about 0.1 to about 100,000 units.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dose of BoNT is from about 1 to about 100 units.

### Claim 10 (depends on 1)

The method of claim 1, wherein the BoNT is combined with a skin permeability enhancing agent.

### Claim 11 (depends on 1)

The method of claim 1, wherein the BoNT is combined with a gel.

### Claim 12 (depends on 11)

The method of claim 11, wherein the viscosity of the gel increases after administration.

### Claim 13 (depends on 11)

The method of claim 11, wherein the gel is a temperature sensitive poloxamer.

### Claim 14 (depends on 1)

The method of claim 1, wherein the BoNT is applied with a penetration enhancing agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the penetration enhancing agent is selected from the group consisting of allergen, histamine, and electrical stimulation.

### Claim 16

A method of treating a nasal or sinus condition, or a symptom thereof, comprising administering a therapeutically effective amount of botulinum toxin (BoNT) by jet or pressure injection to a selected site of a mammal suffering from a nasal or sinus condition, or symptom thereof, wherein the nasal or sinus condition, or symptom thereof, is treated.
